Pharming Group NV reports results for the quarter ended December 31 - Earnings Summary
13/03/2025 07:00
Pharming Group NV PHAR.AS reported quarterly adjusted earnings of 1 cent per share for the quarter ended December 31, higher than the same quarter last year, when the company reported breakeven earnings per share. The mean expectation of three analysts for the quarter was for earnings of one cent per share. Wall Street expected results to range from zero cents to 1 cents per share. Revenue rose 14.1% to $92.67 million from a year ago; analysts expected $80.74 million. Pharming Group NV's reported EPS for the quarter was 1 cent. The company reported quarterly net income of $3.67 million. FORECAST CHANGES The mean earnings estimate of analysts was unchanged in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy." Wall Street's median 12-month price target for Pharming Group NV is €2.10 This summary was machine generated from LSEG data March 13 at 07:00 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | 0.01 | 0.01 | Met |
| Sep. 30 2024 | 0.00 | 0.00 | Met |
| Jun. 30 2024 | 0.01 | -0.01 | Missed |
| Mar. 31 2024 | 0.01 | -0.02 | Missed |